Human Epidermal Growth Factor Improves Atopic Disease-like Skin Lesions in DFE/DNCB Induced BALB/c Mice and Human Keratinocytes
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
PURPOSE: Atopic skin disease is an inflammatory disease with a multifactorial pathogenesis that presents as itchy, dry skin. Human epidermal growth factor (EGF) plays an essential role in regulating cell growth, proliferation, and differentiation. Accordingly, this study aimed to investigate the effects of EGF on atopic diseases. METHODS: Atopic disease was induced by the Dermatophagoides farinae house dust mite extract and 2,4-dinitrochlorobenzene in BALB/c mice. The mice were divided into the following five atopic disease induction and treatment groups: control, atopic disease only, atopic disease+epidermal growth factor-1, atopic disease+epidermal growth factor-10, and positive control atopic disease+ceramide. We examined dermal and epidermal ear thickness, mast cell and T cell infiltration, serum immunoglobulin E and immunoglobulin G2a levels, and mRNA expression of pathogenic cytokines in murine ear tissue and human keratinocyte cells. RESULTS: Epidermal growth factor treatment increased epidermal and dermal ear thickness and inhibited mast and T cell infiltration in the ear in a dose-dependent manner. Treatment also suppressed immunoglobulin E and G2a levels and the mRNA expression of pathogenic cytokines in murine ear tissue and human keratinocytes. The therapeutic outcome of epidermal growth factor was stronger than that of the positive control ceramide. CONCLUSIONS: EGF may be beneficial in the treatment of atopic disease.
Abstract
PURPOSE: Atopic skin disease is an inflammatory disease with a multifactorial pathogenesis that presents as itchy, dry skin. Human epidermal growth factor (EGF) plays an essential role in regulating cell growth, proliferation, and differentiation. Accordingly, this study aimed to investigate the effects of EGF on atopic diseases. METHODS: Atopic disease was induced by the Dermatophagoides farinae house dust mite extract and 2,4-dinitrochlorobenzene in BALB/c mice. The mice were divided into the following five atopic disease induction and treatment groups: control, atopic disease only, atopic disease+epidermal growth factor-1, atopic disease+epidermal growth factor-10, and positive control atopic disease+ceramide. We examined dermal and epidermal ear thickness, mast cell and T cell infiltration, serum immunoglobulin E and immunoglobulin G2a levels, and mRNA expression of pathogenic cytokines in murine ear tissue and human keratinocyte cells. RESULTS: Epidermal growth factor treatment increased epidermal and dermal ear thickness and inhibited mast and T cell infiltration in the ear in a dose-dependent manner. Treatment also suppressed immunoglobulin E and G2a levels and the mRNA expression of pathogenic cytokines in murine ear tissue and human keratinocytes. The therapeutic outcome of epidermal growth factor was stronger than that of the positive control ceramide. CONCLUSIONS: EGF may be beneficial in the treatment of atopic disease.
참고문헌 (30)
- Bieber T, "Allergen-specific immunotherapy: current concepts and future directions: editorial", Allergy, 66(6), pp.709~712 (2011)[DOI]
- Bieber T, "Atopic dermatitis", N Engl J Med, 358(14), pp.1483~1494 (2008)[DOI]
- Sajić D, "A look at epidermal barrier function in atopic dermatitis : physiologic lipid replacement and the role of ceramides", Skin Therapy Lett, 17(7), pp.6~9 (2012)
- Cooper KD, "Atopic dermatitis: recent trends in pathogenesis and therapy", J Invest Dermatol, 102(1), pp.128~137 (1994)[DOI]
- Kabashima-Kubo R, "A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type", J Dermatol Sci, 67(1), pp.37~43 (2012)[DOI]
- Grewe M, "A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis", Immunol Today, 19(8), pp.359~361 (1998)[DOI]
- Hamid Q, "Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis", J Clin Invest, 94(2), pp.870~876 (1994)[DOI]
- Yamada N, "Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects", J Allergy Clin Immunol, 96(6), pp.1069~1075 (1995)[DOI]
- Vestergaard C, "Overproduction of Th2-specific chemokines in NC", Nga mice exhibiting atopic dermatitis-like lesions, 1999, pp.104(8), 1097~1105
- Rothenberg ME, "Common variants at 5q22 associate with pediatric eosinophilic esophagitis", Nat Genet, 42(4), pp.289~291 (2010)[DOI]
- He R, "Thymic stromal lymphopoietin", Ann N Y Acad Sci, 1183, pp.13~24 (2010)[DOI]
- Venge P, "Eosinophil and neutrophil granulocytes", Allergy, 48(s17), pp.39~47 (1993)[DOI]
- Carpenter G, "Epidermal growth factor", J Biol Chem, 265(14), pp.7709~7712 (1990)[DOI]
- Cohen S, "The stimulation of epidermal keratinization by a protein isolated from the submaxillary gland of the mouse", J Invest Dermatol, 92(4 Suppl), pp.157S~ (1989)[DOI]
- Herbst RS, "Review of epidermal growth factor receptor biology", Int J Radiat Oncol Biol Phys, 59(2 Suppl), pp.21~26 (2004)[DOI]
- Alexander PB, "EGF promotes mammalian cell growth by suppressing cellular senescence", Cell Res, 25(1), pp.135~138 (2015)[DOI]
- 이장헌, "Topical application of epidermal growth factor accelerates wound healing by myofibroblast proliferation and collagen synthesis in rat", Journal of Veterinary Science, 7(2), pp.105~109 (2006), 대한수의학회
- Kim SH, "High-intensity swimming exercise increases dust mite extract and 1-chloro-2, 4-dinitrobenzene-derived atopic dermatitis in BALB", c mice, 2014, pp.37(4), 1179~1185
- Lee HS, "Oral administration of p-hydroxycinnamic acid attenuates atopic dermatitis by downregulating Th1 and Th2 cytokine production and keratinocyte activation", PLoS One, 11(3), pp.e0150952~ (2016)[DOI]
- Okumura K, "Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF", Pharm Res, 7(12), pp.1289~1293 (1990)[DOI]
- Kong M, "Topical use of recombinant human epidermal growth factor(EGF)-based cream to prevent radiation dermatitis in breast cancer patients : a single-blind randomized preliminary study", Asian Pac J Cancer Prev, 14(8), pp.4859~4864 (2013)[DOI]
- Dokmeci E, "The immune system and atopic dermatitis", Semin Cutan Med Surg, 27(2), pp.138~143 (2008)[DOI]
- Chen L, "Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model", Clin Exp Immunol, 138(3), pp.375~387 (2004)[DOI]
- Neis MM, "Enhanced expression levels of IL31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis", J Allergy Clin Immunol, 118(4), pp.930~937 (2006)[DOI]
- Mathlouthi M, "Vibrational spectra of carbohydrates", Adv Carbohydr Chem Biochem, 44, pp.7~89 (1986)[DOI]
- Cianferoni A, "The importance of TSLP in allergic disease and its role as a potential therapeutic target", Expert Rev Clin Immunol, 10(11), pp.1463~1474 (2014)[DOI]
- Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP", Nat Immunol, 3(7), pp.673~680 (2002)[DOI]
- Boniface K, "Keratinocytes as targets for interleukin-10-related cytokines : a putative role in the pathogenesis of psoriasis", Eur Cytokine Netw, 16(4), pp.309~319 (2005)
- Boniface K, "IL-22inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes", J Immunol, 174(6), pp.3695~3702 (2005)[DOI]
- Bogiatzi SI, "Cutting edge : proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes", J Immunol, 178(6), pp.3373~3377 (2007)[DOI]